יחס חוב לטווח ארוך להון alaunos.com (TCRT)

Future revenues for Alaunos Therapeutics (TCRT) rely on the implementation of personalized TCR-T therapies for solid tumors via the Sleeping Beauty system. Meanwhile, market quotes already price in past test failures, while new growth catalysts are expected in the long term. This chart reflects a market trend value of 0.00, while the business currently generates revenue from grants while developing cell-based therapies.

The success of Alaunos Therapeutics (TCRT) depends directly on the outcomes of T-cell therapy clinical trials. The long-term debt-to-equity ratio measures the proportion of borrowed financing with a maturity of more than one year. This ratio determines the company's financial autonomy and its resilience to liquidity shortages. This helps the investor assess the risk of bankruptcy in the event that inefficient programs are closed. The trend in the long-term debt-to-equity ratio confirms the current safety of reserves.